Simultaneous curative resection may improve the long-term survival of patients diagnosed with colorectal liver metastases: A propensity score–matching study
Xianmao Shi(Guangxi Medical University), Weizhong Tang(Guangxi Medical University), Tao Luo(Guangxi Medical University), Hualin Wu(Guangxi Medical University), Shun Lü(Shanghai Jiao Tong University), Jie Chen(Sun Yat-sen University), Qingyuan Zhang(Harbin Medical University), Xiaobo Wang(Centre National de la Recherche Scientifique), Chunliu Huang(Sun Yat-sen University)
Cited by 2
Related Papers
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Osimertinib in Resected <i>EGFR</i> -Mutated Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2020|1.7k
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials
|The Lancet Oncology|2015|1.6k
Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial
|The Lancet Oncology|2016|1.2k
Overall Survival with Osimertinib in Resected <i>EGFR</i> -Mutated NSCLC
|New England Journal of Medicine|2023|605